381 related articles for article (PubMed ID: 25907622)
1. Clinical outcomes in a contemporary series of "young" patients with castration-resistant prostate cancer who were 60 years and younger.
Caffo O; Ortega C; Di Lorenzo G; Sava T; De Giorgi U; Cavaliere C; Macrini S; Spizzo G; Aieta M; Messina C; Tucci M; Lodde M; Mansueto G; Zucali PA; Alesini D; D'Angelo A; Massari F; Morelli F; Procopio G; Ratta R; Fratino L; Lo Re G; Pegoraro MC; Zustovich F; Vicario G; Ruatta F; Federico P; La Russa F; Burgio SL; Maines F; Veccia A; Galligioni E
Urol Oncol; 2015 Jun; 33(6):265.e15-21. PubMed ID: 25907622
[TBL] [Abstract][Full Text] [Related]
2. Optimal sequencing of docetaxel and abiraterone in men with metastatic castration-resistant prostate cancer.
Maughan BL; Xhou XC; Suzman DL; Nadal R; Bassi S; Schweizer MT; Antonarakis ES
Prostate; 2015 Nov; 75(15):1814-20. PubMed ID: 26306637
[TBL] [Abstract][Full Text] [Related]
3. CAST: A retrospective analysis of cabazitaxel and abiraterone acetate sequential treatment in patients with metastatic castrate-resistant prostate cancer previously treated with docetaxel.
Wissing MD; Coenen JL; van den Berg P; Westgeest HM; van den Eertwegh AJ; van Oort IM; Bos MM; Bergman AM; Hamberg P; Ten Tije AJ; Los M; Lolkema MP; de Wit R; Gelderblom H
Int J Cancer; 2015 Mar; 136(6):E760-72. PubMed ID: 25242736
[TBL] [Abstract][Full Text] [Related]
4. A retrospective, Canadian multi-center study examining the impact of prior response to abiraterone acetate on efficacy of docetaxel in metastatic castration-resistant prostate cancer.
Azad AA; Leibowitz-Amit R; Eigl BJ; Lester R; Wells JC; Murray RN; Kollmannsberger C; Heng DY; Joshua AM; Chi KN
Prostate; 2014 Nov; 74(15):1544-50. PubMed ID: 25175831
[TBL] [Abstract][Full Text] [Related]
5. Safety and Clinical Outcomes of Abiraterone Acetate After Docetaxel in Octogenarians With Metastatic Castration-Resistant Prostate Cancer: Results of the Italian Compassionate Use Named Patient Programme.
Maines F; Caffo O; De Giorgi U; Fratino L; Lo Re G; Zagonel V; D'Angelo A; Donini M; Verderame F; Ratta R; Procopio G; Campadelli E; Massari F; Gasparro D; Ermacora P; Messina C; Giordano M; Alesini D; Basso U; Fraccon AP; Vicario G; Conteduca V; Galligioni E
Clin Genitourin Cancer; 2016 Feb; 14(1):48-55. PubMed ID: 26382222
[TBL] [Abstract][Full Text] [Related]
6. Oncological outcome of docetaxel-based chemotherapy for Japanese men with metastatic castration-resistant prostate cancer.
Miyake H; Sakai I; Terakawa T; Harada K; Fujisawa M
Urol Oncol; 2013 Aug; 31(6):733-8. PubMed ID: 21782481
[TBL] [Abstract][Full Text] [Related]
7. Initial biopsy Gleason score as a predictive marker for survival benefit in patients with castration-resistant prostate cancer treated with docetaxel: data from the TAX327 study.
van Soest RJ; de Morrée ES; Shen L; Tannock IF; Eisenberger MA; de Wit R
Eur Urol; 2014 Aug; 66(2):330-6. PubMed ID: 23957945
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of docetaxel-based chemotherapy following ketoconazole in metastatic castration-resistant prostate cancer: implications for prior therapy in clinical trials.
Pond GR; Armstrong AJ; Galsky MD; Wood BA; Leopold L; Sonpavde G
Urol Oncol; 2013 Nov; 31(8):1457-63. PubMed ID: 22552048
[TBL] [Abstract][Full Text] [Related]
9. Prostate-specific antigen flare induced by cabazitaxel-based chemotherapy in patients with metastatic castration-resistant prostate cancer.
Angelergues A; Maillet D; Fléchon A; Ozgüroglu M; Mercier F; Guillot A; Le Moulec S; Gravis G; Beuzeboc P; Massard C; Fizazi K; de La Motte Rouge T; Delanoy N; Elaidi RT; Oudard S
Eur J Cancer; 2014 Jun; 50(9):1602-9. PubMed ID: 24725337
[TBL] [Abstract][Full Text] [Related]
10. Response to subsequent docetaxel in a patient cohort with metastatic castration-resistant prostate cancer after abiraterone acetate treatment.
Aggarwal R; Harris A; Formaker C; Small EJ; Molina A; Griffin TW; Ryan CJ
Clin Genitourin Cancer; 2014 Oct; 12(5):e167-72. PubMed ID: 24787968
[TBL] [Abstract][Full Text] [Related]
11. Treatment outcome of docetaxel plus prednisolone for metastatic castration-resistant prostate cancer in Korea.
Cho IC; Joung JY; Seo HK; Chung J; Park WS; Lee KH
J Cancer Res Ther; 2014; 10(2):251-7. PubMed ID: 25022374
[TBL] [Abstract][Full Text] [Related]
12. Second-Line Cabazitaxel Treatment in Castration-Resistant Prostate Cancer Clinical Trials Compared to Standard of Care in CAPRI: Observational Study in the Netherlands.
Westgeest HM; Kuppen MCP; van den Eertwegh AJM; de Wit R; Coenen JLLM; van den Berg HPP; Mehra N; van Oort IM; Fossion LMCL; Hendriks MP; Bloemendal HJ; van de Luijtgaarden ACM; Ten Bokkel Huinink D; van den Bergh ACMF; van den Bosch J; Polee MB; Weijl N; Bergman AM; Uyl-de Groot CA; Gerritsen WR
Clin Genitourin Cancer; 2019 Oct; 17(5):e946-e956. PubMed ID: 31439536
[TBL] [Abstract][Full Text] [Related]
13. Activity of cabazitaxel after docetaxel and abiraterone acetate therapy in patients with castration-resistant prostate cancer.
Sella A; Sella T; Peer A; Berger R; Frank SJ; Gez E; Sharide D; Hayat H; Hanovich E; Kovel S; Rosenbaum E; Neiman V; Keizman D
Clin Genitourin Cancer; 2014 Dec; 12(6):428-32. PubMed ID: 25066221
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and toxicity of abiraterone and docetaxel in octogenarians with metastatic castration-resistant prostate cancer.
Leibowitz-Amit R; Templeton AJ; Alibhai SM; Knox JJ; Sridhar SS; Tannock IF; Joshua AM
J Geriatr Oncol; 2015 Jan; 6(1):23-8. PubMed ID: 25301537
[TBL] [Abstract][Full Text] [Related]
15. Docetaxel Activity in the Era of Life-prolonging Hormonal Therapies for Metastatic Castration-resistant Prostate Cancer.
Francini E; Sweeney CJ
Eur Urol; 2016 Sep; 70(3):410-2. PubMed ID: 27184379
[TBL] [Abstract][Full Text] [Related]
16. Sequencing of Cabazitaxel and Abiraterone Acetate After Docetaxel in Metastatic Castration-Resistant Prostate Cancer: Treatment Patterns and Clinical Outcomes in Multicenter Community-Based US Oncology Practices.
Sonpavde G; Bhor M; Hennessy D; Bhowmik D; Shen L; Nicacio L; Rembert D; Yap M; Schnadig I
Clin Genitourin Cancer; 2015 Aug; 13(4):309-318. PubMed ID: 25743206
[TBL] [Abstract][Full Text] [Related]
17. Rational indication for docetaxel rechallenge in metastatic castration-resistant prostate cancer.
Heck MM; Thalgott M; Retz M; Wolf P; Maurer T; Nawroth R; Hatzichristodoulou G; Gschwend JE; Kübler H
BJU Int; 2012 Dec; 110(11 Pt B):E635-40. PubMed ID: 22889368
[TBL] [Abstract][Full Text] [Related]
18. Abiraterone acetate and prednisolone for metastatic castration-resistant prostate cancer failing androgen deprivation and docetaxel-based chemotherapy: a phase II bridging study in Korean and Taiwanese patients.
Kwak C; Wu TT; Lee HM; Wu HC; Hong SJ; Ou YC; Byun SS; Rhim HY; Kheoh T; Wan Y; Yeh H; Yu MK; Kim CS
Int J Urol; 2014 Dec; 21(12):1239-44. PubMed ID: 25099185
[TBL] [Abstract][Full Text] [Related]
19. Clinical Impact of the Number of Treatment Cycles in First-Line Docetaxel for Patients With Metastatic Castration-Resistant Prostate Cancer.
Kongsted P; Svane IM; Lindberg H; Sengeløv L
Clin Genitourin Cancer; 2017 Apr; 15(2):e281-e287. PubMed ID: 27692811
[TBL] [Abstract][Full Text] [Related]
20. Docetaxel rechallenge after an initial good response in patients with metastatic castration-resistant prostate cancer.
Oudard S; Kramer G; Caffo O; Creppy L; Loriot Y; Hansen S; Holmberg M; Rolland F; Machiels JP; Krainer M
BJU Int; 2015 May; 115(5):744-52. PubMed ID: 24947139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
